Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis.
Jaleh FallahHaley GittlemanChana WeinstockElaine ChangSundeep AgrawalShenghui TangRichard PazdurPaul G KluetzDaniel L SuzmanLaleh Amiri-KordestaniPublished in: Journal of the National Cancer Institute (2024)
Patients with metastatic renal cell carcinoma who undergo cytoreductive nephrectomy before immune checkpoint inhibitor plus antiangiogenic therapy had improved outcomes compared with patients without cytoreductive nephrectomy. Selection factors for cytoreductive nephrectomy may be prognostic and could not be fully controlled for in this retrospective analysis. Prospective determination of and stratification by prior cytoreductive nephrectomy may be considered when designing clinical trials to assess the impact of this factor on prognosis.
Keyphrases
- metastatic renal cell carcinoma
- robot assisted
- editorial comment
- clinical trial
- end stage renal disease
- drug administration
- ejection fraction
- chronic kidney disease
- newly diagnosed
- minimally invasive
- randomized controlled trial
- type diabetes
- risk assessment
- metabolic syndrome
- adipose tissue
- mesenchymal stem cells
- human health
- replacement therapy
- molecularly imprinted
- phase iii